Document:

exv10w2

Exhibit 10.2

AMENDMENT No. 1

     This
Amendment No. 1 (the “Amendment”) is entered into as of the 25th day of
November, 2009 (“Amendment No. 1 Date”) by and among Human Genome Sciences, Inc., a
Delaware corporation having its principal place of business at 14200 Shady Grove Road, Rockville,
Maryland 20850 (“HGS”) and Glaxo Group Limited, a company organized under the laws of
England and Wales with its principal place of business at GlaxoWellcome House, Berkeley Avenue,
Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). HGS and GSK are hereinafter
individually referred to as a “Party” and collectively as the “Parties.”

WHEREAS, GSK owns certain GSK Arising Patents (as defined in the Agreement) which GSK has licensed
to HGS pursuant to a Co-Development and Commercialization Agreement between HGS and GSK dated
August 2, 2006 (the “Agreement”); and

WHEREAS, GSK and its Affiliate, GlaxoSmithKline LLC (formerly known as SmithKline Beecham
Corporation), own certain GSK Existing Patent Rights and GSK Additional Patent Rights (as defined
below) related to the subject matter of the Agreement, which GSK is willing to license to HGS on
the terms of this Amendment in order to further the Parties’ common interest in developing and
commercializing belimumab.

Now, therefore, in consideration of the foregoing premises and the representations, covenants and
agreements contained herein, the Parties hereby agree as follows:

1. DEFINITIONS

     1.1 “GSK Existing Patent Rights” shall mean rights under the following patents and
patent applications: [***] and any and all patents that are issued therefrom, together with any and
all substitutions, continuations, divisionals, continuations-in-part, reissues, renewals,
registrations, confirmations, reexaminations, extensions including supplementary protection
certificates, foreign equivalents or counterparts, and other filings thereof.

     1.2 “GSK Additional Patent Rights” shall mean rights under the following patents and
patent applications: [***] and any and all patents that are issued therefrom, together with any and
all substitutions, continuations, divisionals, continuations-in-part, reissues, renewals,
registrations, confirmations, reexaminations, extensions including supplementary protection
certificates, foreign equivalents or counterparts, and other filings thereof. GSK Additional
Patent Rights shall also include rights under any patents or patent applications (other than GSK
Arising Patents) which are owned or Controlled

 

			
	[***]	 	INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR
WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS
BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

by GSK or any of its Affiliates during the Term that claim the Development and/or
Commercialization of belimumab or Collaboration Product.

     1.3 Except as set forth herein, all other capitalized terms herein shall have the same meaning
as defined in the Agreement.

2. AMENDMENTS.

     2.1 The Parties amend Section 1.16 of the Agreement as follows:

“Collaboration Technology” shall mean HGS Existing Patent Rights, HGS Existing Know-How, GSK
Existing Patent Rights, GSK Arising Patent Rights, GSK Arising Know-How, HGS Arising Patent Rights,
HGS Arising Know-How, Joint Arising Patent Rights and Joint Arising Know-How.”

     2.2 The Parties agree that each reference to “GSK Arising Patent Rights” shall be amended to
“GSK Existing Patent Rights, GSK Additional Patent Rights and GSK Arising Patent Rights” in the
following provisions of the Agreement: Sections 2.2.1, 2.5, 12.4.1 and 12.4.3.

     2.3 The Parties agree that each reference to “Collaboration Technology” shall be amended to
“Collaboration Technology and GSK Additional Patent Rights” in the following provisions of the
Agreement: Sections 2.3.3, 2.3.4 and 13.6.

     2.4 The Parties agree that each reference to “GSK Arising Patent Rights” shall be amended to
“GSK Existing Patent Rights and GSK Arising Patent Rights” in the following provisions of the
Agreement: Sections 10.1, 10.2.1, 10.2.3, 10.4.4, 10.4.5 and 13.5.

     2.5 Notwithstanding any terms to the contrary in this Amendment or in the Agreement, HGS shall
have no responsibility or obligation to GSK for any costs or expenses relating to the GSK Existing
Patent Rights incurred prior to the Amendment No. 1 Date.

     2.6 Notwithstanding any terms to the contrary in this Amendment or in the Agreement, Section
10.4.6 of the Agreement shall not apply to any statements regarding the GSK Existing Patent Rights
made by HGS prior to the Amendment No. 1 Date.

2

 

     2.7 The Parties agree that the following wording shall be added to the end of Section 12.4.2:

“Furthermore, all rights and licenses granted hereunder by GSK to HGS under the GSK Additional
Patent Rights shall immediately terminate and HGS shall have no right to any continued use of the
GSK Additional Patent Rights. Upon request from HGS, GSK shall negotiate in good faith terms under
which HGS could continue to exercise rights under
the GSK Additional Patent Rights in relation to Collaboration Products.”

3. COMMUNITY OF LEGAL INTEREST.

     3.1 For the avoidance of doubt, the Parties hereby acknowledge that they have a common legal
interest in enforcing and defending the GSK Existing Patent Rights and GSK Additional Patent
Rights, and the Community of Legal Interest Agreement entered into by the Parties dated
1st August 2006 also applies to the GSK Existing Patent Rights and GSK Additional Patent
Rights for the term of this Amendment.

4. APPROVAL OF GLAXOSMITHKLINE LLC

     4.1 GlaxoSmithKline LLC (“SBCorp”) hereby consents to GSK granting to HGS rights under
SBCorp’s interests in the GSK Additional Patent Rights on the terms set out in this Amendment. To
the extent that SBCorp needs to grant GSK a license under the GSK Additional Patent Rights in order
to enable GSK to grant the rights herein to HGS, SBCorp hereby grants such license.

5. TERM 

     5.1 Term. The terms of this Amendment shall be effective from the Effective Date of
the Agreement and shall continue until the expiry or termination of the Agreement.

6. MISCELLANEOUS

     6.1 All other terms and conditions of the Agreement shall remain in full force and effect.
This Amendment, together with the Agreement, the Community of Legal Interest Agreement dated
1st August 2006, the Side Letter Agreement dated 14th April 2008, and the
Side Letter Agreement dated 24th June 2009, constitutes the entire agreement between the
Parties relating to the subject matter hereof and supersedes all previous writings and
understandings relating to such subject matter.

     6.2 This Agreement may be executed in counterparts with the same effect as if HGS, GSK and
SBCorp had signed the same document. All such counterparts shall be deemed an original, shall be
construed together and shall constitute one and the same instrument.

[Signature Page
Follows]

 

 

     IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their respective
duly authorized officers as of the Amendment No. 1 Date.

	 	 	 	 	 

	 	HUMAN GENOME SCIENCES, INC.	 
	 
	 	 	 	 
	 	By:

	 	/s/ James H. Davis	 
	 

	 	 	 

	 
	 	Name:

	 	James H. Davis	 
	 	Title:

	 	Executive Vice President & General Counsel	 
	 
	 	 	 	 
	 	GLAXO GROUP LIMITED	 
	 
	 	 	 	 
	 	By:

	 	/s/ Paul Williamson	 
	 	 

	 	 

	 
	 	Name:

	 	Paul Williamson	 
	 	Title:

	 	Corporate Director	 
	 
	 	 	 	 
	 	GLAXOSMITHKLINE LLC (formerly known as

SMITHKLINE BEECHAM CORPORATION)	 
	 
	 	 	 	 
	 	By:

	 	/s/ William J. Mosher	 
	 	 

	 	 

	 
	 	Name:

	 	William J. Mosher	 
	 	Title:

	 	Vice President and Secretary	 

4exv10w3

Exhibit 10.3

AMENDMENT NO. 2 TO THE

CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

     THIS AMENDMENT NO. 2 TO THE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”) is
made and entered into as of the 5th day of October 2010 (the “Effective Date”) by and
between GLAXO GROUP LIMITED, a company organized under the laws of England and Wales with its
principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6
0NN, United Kingdom (“GSK”) and HUMAN GENOME SCIENCES, INC., a Delaware corporation with its
principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (“HGS”). GSK and
HGS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

     WHEREAS, GSK and HGS entered into a Co-Development and Commercialization Agreement dated as of
August 1, 2006, as amended on November 25, 2009 (collectively, the “Co-Development and
Commercialization Agreement”);

     WHEREAS, the Parties recognize that Policy Disputes (as defined below) between the Parties may from
time to time arise under the Co-Development and Commercialization Agreement; and

     WHEREAS, the Parties desire to establish separate procedures to facilitate the resolution of such
Policy Disputes in an expedient manner by mutual cooperation as set forth in this Amendment.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises, terms and
conditions hereafter set forth, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, GSK and HGS hereby agree to be legally bound as
follows:

ARTICLE 1

DEFINITIONS

     1.1 New Defined Terms. The following terms shall be added to Article 1 of the
Co-Development and Commercialization Agreement in alphabetical order:

     1.1.1 “Designated Expert” shall mean a specialist healthcare/regulatory attorney
listed on Schedule A attached to Amendment No. 2 to the Co-Development and
Commercialization Agreement, or other individual(s) as may be mutually agreed between the
Parties in writing.

     1.1.2 “More Conservative Approach” shall mean, in the event of a dispute between the
Parties on how to address or resolve a certain issue arising under the Co-Development and
Commercialization Agreement (including without limitation any Policy Disputes), the
approach or position offered by a Party with

 

 

respect to the resolution of such issue, which
approach or position, in the aggregate, is reasonably likely to expose the Parties or the
Collaboration Products to the smallest amount of legal, regulatory and/or compliance risk,
whether or not
such opinion of a Party is set forth in such Party’s then-current internal policies
regarding the same, provided that such approach is not Unreasonably Conservative.

     1.1.3 “Other Dispute” shall mean any dispute between the Parties relating to the
Agreement other than a Policy Dispute.

     1.1.4 “Policy Dispute” shall mean a difference of opinion between the Parties
regarding the permissibility of specific sales, marketing or medical affairs activities in
the Territory by GSK and/or HGS.

     1.1.5 “Unreasonably Conservative” shall mean, with respect to an approach or position
offered by a Party in order to address or resolve an issue, that such approach or position
is unreasonably conservative in light of the business implications of the approach and
overall consistency with industry best practices as implemented by similarly-situated peer
companies of such Party and documented in applicable guidances (including, with respect to
the United States, the Department of Health and Human Services Office of Inspector General
Compliance Program Guidance, the Pharmaceutical Research and Manufacturers of America Code
on Interactions with Healthcare Professionals, the American Council for Continuing Medical
Education Guidelines, and similar guidances).

     1.2 Amended Defined Terms. The following term, as used in the Co-Development and
Commercialization Agreement, are hereby deleted in their entirety and replaced with the following:

     1.2.1 “Laws” shall mean all laws, statutes, rules, regulations, ordinances, guidances
and other pronouncements, including without limitation, corporate integrity agreements,
having the effect of law of any government or Governmental Authority.

     1.3 Other Defined Terms. All other capitalized terms included in this Amendment that
are not defined herein shall have the meaning ascribed to such terms in the Co-Development and
Commercialization Agreement.

ARTICLE 2

RESOLUTION OF POLICY DISPUTES

     2.1 Amendment to Article 3.

     2.1.1 Amendment to Section 3.1.3. Section 3.1.3 of the Co-Development and
Commercialization Agreement is hereby deleted in its entirety and replaced with the
following:

- 2 -

 

     “Decision Making. All decisions of the JSC shall be made by unanimous vote,
with each Party having one vote. Reasonable efforts will be made to come
to a consensus decision. With respect to any issue, if the Joint Steering Committee
cannot reach consensus within ten (10) business days after the matter has been brought to
the Joint Steering Committee’s attention, either Party may elect to have such issue
resolved in accordance with Article 15 of this Agreement.”

     2.2 Amendments to Article 5.

     2.2.1 Amendment to Section 5.5.1. Section 5.5.1 of the Co-Development and
Commercialization Agreement is hereby amended by:

     2.2.1.1 deleting in its entirety the third sentence thereof and inserting the
following language in lieu thereof:

     “No Party shall be required to undertake, participate in, finance or otherwise support
any activity under this Agreement which it believes, in good faith, may violate or conflict
with that Party’s policies or any applicable Law.”

     2.2.1.2 deleting in its entirety the last sentence thereof and inserting the
following language in lieu thereof:

     “In the event of a conflict between the policies of each Party with respect to
Promotional Materials or Co-Promotion and Detailing activities, the GJMC or the relevant
RJMC shall determine which policy will be followed; provided, however, that for clarity,
any disputes within the GJMC or RJMC regarding any of the foregoing, including without
limitation, any Policy Disputes, shall be resolved in accordance with Article 3 and if
required, finally in accordance with Article 15.”

     2.2.2 Amendment to add Section 5.9. A new Section 5.9 is hereby added to the
Co-Development and Commercialization Agreement as follows:

     “5.9 Independent Third Party Reviews.

     5.9.1 Each Party shall have the right to engage a Third Party (the “Reviewer”)
to conduct periodic, independent reviews of the other Party’s compliance program as
applicable to the Collaboration Product, with a particular focus on sales,
marketing and medical affairs activities, or other activities which are reasonably
likely to expose the Parties requesting the review to legal, regulatory and/or
compliance risk (a “Review”). The purpose of the Review is to determine, inter
alia, whether the other Party’s current compliance systems, policies, processes and
procedures are functioning properly and are consistent with
applicable guidelines and

- 3 -

 

industry best practices. The scope of any such Review must be mutually agreed
by the Parties prior to its initiation, which agreement by a Party shall not be
unreasonably withheld.

     5.9.2 Either Party may, at any time during the Term, initiate a Review of the
other Party by giving written notice to the other Party, provided that such reviews
of the same or similar scope may be requested no more frequently than once per
calendar year.

     5.9.3 The Parties shall mutually select the Reviewer, and the Review must
begin within a reasonable time thereafter, but in any event within ninety (90)
calendar days after the date of the written notice pursuant to which a Party
initiates the Review, as set forth in Section 5.9.2. The Parties may mutually
elect to limit a review to only one of the Parties.

     5.9.4 The Reviewer shall prepare a written report of his/her findings, a copy
of which report shall be provided to each Party. The Party that was subject to the
Review will be required to adequately address any findings or deficiencies noted by
the Reviewer within a reasonable period of time after completion of the Review.

     5.9.5 The Parties will equally share the cost of the Reviewer.”

     2.2 Amendments to Article 15.

     2.2.1 Amendment to Section 15.1. Section 15.1 shall be deleted in its
entirety and replaced with the following:

     “15.1 Resolution of Other Disputes and Policy Disputes.

     15.1.1 Other Disputes. If the JSC cannot in good faith reach a
consensus within ten (10) business days (or such later date as may be mutually
agreed in writing by the Parties) after such Other Dispute has been referred to the
JSC for resolution as provided in Section 3.1.3 of this Agreement, then either
Party shall have a right to refer such Dispute to the following individuals (in
each case, the “Senior Officers”) for resolution as follows: (i) all Other
Disputes relating to Development of a Collaboration Product shall be elevated to
GSK’s Chairman of Research and Development and HGS’ Chief Executive Officer
(“CEO”), or their respective designees, for resolution, (ii) all Other Disputes
relating to Manufacturing of Collaboration Product shall be elevated to GSK’s
President of Global Manufacturing and Supply and HGS’ CEO, or their respective
designees, for resolution, and (iii) all Other Disputes relating to the
Commercialization of a Collaboration Product or any other items not covered in (i)
or (ii) above shall be elevated to GSK’s President of

- 4 -

 

Pharmaceutical Operations and
HGS’ CEO, or their respective designees, for resolution. If the Senior Officers
are unable to reach a resolution with respect to an Other Dispute within ten (10)
business days after a Party
requests for such Senior Officers to resolve an issue, the Other Dispute shall
be resolved pursuant to Section 15.2.

     15.1.2 Policy Disputes. If the JSC cannot in good faith reach a
consensus within ten (10) business days (or such later date as may be mutually
agreed in writing by the Parties) after such a Policy Dispute has been referred to
the JSC for resolution as provided in Section 3.1.3 of this Agreement, then the
compliance attorneys and senior legal and commercial officers (collectively, the
“Policy Officers”) of each Party shall in good faith attempt to resolve the Policy
Dispute. If the Policy Officers are unable reach a resolution with respect to a
Policy Dispute within ten (10) business days (or such later date as may be mutually
agreed in writing by the Parties) after such Policy Dispute has been brought to the
attention of the Policy Officers, then the Policy Dispute shall be resolved
pursuant to Section 15.3.”

     2.2.2 Amendment to Section 15.2. The heading of Section 15.2 shall be deleted
and replaced with the following “Arbitration for Other Disputes.” Furthermore, all
references in Section 15.2 to “dispute” shall be replaced with “Other Dispute”.

     2.2.3 New Section 15.3. The following shall be inserted into the Agreement as
Section 15.3:

     “15.3 Resolution of Policy Disputes.

          15.3.1 If, despite good faith efforts, the Policy Officers are unable to resolve a
Policy Dispute within ten (10) business days (or such later date as may be mutually agreed
in writing by the Parties) after such matter has been referred to them, then the More
Conservative Approach shall be selected and followed by the Parties. If the Policy
Officers cannot agree on which approach or position offered by the Parties is the More
Conservative Approach with respect to a particular issue or whether the More Conservative
Approach is Unreasonably Conservative, then either Party may, by written notice to the
other Party (a “Notice of Referral”), refer the Policy Dispute to a Designated Expert for
resolution in accordance with Section 15.3.2.

          15.3.2 Upon delivery of a Notice of Referral with respect to a Policy Dispute, within
three (3) business days following the date of the Notice of Referral, the Parties shall
agree on the selection of a Designated Expert, using whatever selection criteria the
Parties prefer. The Parties shall engage the Designated Expert within three (3) business
days following such Designated Expert’s selection by the Parties. Each Party agrees to
execute, if requested by a

- 5 -

 

Designated Expert, a reasonable engagement letter, including
customary indemnities in favor of the Designated Expert. The fees and other expenses of the
Designated Expert shall be shared equally between the Parties.

          15.3.3 At the time of engagement of the Designated Expert, the Parties shall submit a
joint request for opinion to the Designated Expert (a “Request for Opinion”). The Request
for Opinion shall contain the following:

	 	(a)	 	a very brief description of the disputed
activity or inactivity;
	 
	 	(b)	 	each Party’s proposed resolution of the
Policy Dispute and the reasons supporting such resolution, which
shall be exchanged among the Parties; and
	 
	 	(c)	 	instruction to the Designated Expert to
provide to the Parties, within two (2) business days of the Request
for Opinion, a written opinion of not more than two pages in length
selecting the proposed resolution from one Party which represents the
More Conservative Approach.

Each Party agrees to cooperate with the Designated Expert and to provide any materials and
information reasonably requested by the Designated Expert.

          15.3.4 If a Party believes the More Conservative Approach is Unreasonably
Conservative, that Party shall immediately raise that issue to the Designated Expert for a
determination. If the Designated Expert determines that the More Conservative Approach is
Unreasonably Conservative, the Designated Expert will then review an alternative proposal
offered by the other Party (the
“Alternative Position”) to determine whether such Alternative Position is
“Sufficiently Conservative,” which means that the Alternative Position is not reasonably
likely to expose the Parties to a significant legal, regulatory and/or compliance risk and
is consistent with industry best practices as documented in applicable guidances
(including, with respect to the United States, the Department of Health and Human Services
Office of Inspector General Compliance Program Guidance; the Pharmaceutical Research and
Manufacturers of America Code on Interactions with Healthcare Professionals; the American
Council for Continuing Medical Education Guidelines; and similar guidances and standards
including corporate integrity agreements issued within the industry). If the Designated
Expert determines that the Alternative Position is Sufficiently Conservative, the Parties
shall proceed with the Alternative Position, subject to Section 15.3.5. If the Designated
Expert determines that the Alternative Position is not Sufficiently Conservative, then the
Parties shall submit a follow-on Request for Opinion to the Designated Expert in accordance
with the same procedures set forth in Section 15.3.3, which
Request for Opinion shall include modified proposed resolutions

- 6 -

 

from each Party. This process shall continue until
the Designated Expert selects a proposed resolution that represents the More Conservative
Approach.

          15.3.5 With respect to a Policy Dispute, the Parties agree to be bound by and to
proceed in accordance with the opinion of the Designated Expert which decision shall have
the same effect as a decision by an arbitrator under Section 15.2 of the Co-Development and
Commercialization Agreement; provided, however, that, neither Party shall be required to
undertake, participate in, finance or otherwise support any activity under this Agreement
which it believes, in good faith, may violate or conflict with that Party’s policies, any
applicable Laws, or any Industry Guidelines. Nothing herein shall infringe any Party’s
right to disclose activities to Regulatory Authorities as may be required by applicable
Law.

          15.3.6 All offers, promises, conduct and statements, whether oral or written, made in
the course of the Designated Expert’s review by any of the Parties, their respective
agents, employees, experts and attorneys, and by the Designated Expert, are confidential,
privileged and inadmissible for any purpose, including impeachment, in any litigation or
other proceeding involving the Parties, provided that evidence that is otherwise
admissible or discoverable shall not be rendered inadmissible or non-discoverable as a
result of its use in the Designated Expert’s review process; and further provided
that either Party may waive the privileges contemplated in this Section 15.3.6 upon receipt
of written consent of the other Party which shall not be unreasonably withheld.

     2.3 Addition of Schedule A to the Agreement. Schedule A to this Amendment
shall be added to the Agreement as a new Schedule.

ARTICLE 3

MISCELLANEOUS

     3.1 Scope of this Amendment. Except as explicitly amended above, all terms and
provisions of the Co-Development and Commercialization Agreement shall remain in full force and
effect, except that each reference to the “Agreement” or words of like import in the Co-Development
and Commercialization Agreement will mean and be a reference to the Co-Development and
Commercialization Agreement as amended by this Amendment.

     3.2 Governing Law. This Amendment shall be governed by and construed in accordance
with the laws of Delaware, as if executed and fully performed within Delaware, excluding any
conflicts or choice of law rule or principle that might otherwise refer construction or
interpretation of this Amendment to the substantive law of another jurisdiction. Any disputes
under this Agreement shall be subject to the exclusive jurisdiction and venue of the Delaware state
courts and the Federal courts located in Delaware, and the Parties hereby consent to the personal
and exclusive jurisdiction and venue of these courts.

- 7 -

 

     3.3 Counterparts. This Amendment may be executed in one or more counterparts, each of
which shall be deemed to be an original but all of which together shall constitute one and the same
instrument.

[Remainder
of Page Intentionally Left Blank]

- 8 -

 

     IN WITNESS WHEREOF, each of the Parties has caused this Amendment No. 2 to the Co-Development
and Commercialization Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	 	GLAXO GROUP LIMITED

 	 
	 	By:  	/s/ Paul Williamson
 	 
	 	 	Name:  	Paul Williamson 	 
	 	 	Title:  	Corporate Director 	 
	 
	 	HUMAN GENOME SCIENCES, INC.

 	 
	 	By:  	/s/ James H. Davis, Ph.D.
 	 
	 	 	Name:  	James H. Davis, Ph.D. 	 
	 	 	Title:  	Executive Vice President and General Counsel 	 
	 

 

SCHEDULE A

List of Designated Experts

     [***]

 

			
	[***]	 	INDICATES MATERIAL THAT HAS BEEN OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED
MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]